What does Brainstorm Cell Therapeutics, Inc. do?

Jun 22 2025 06:44 PM IST
share
Share Via
Brainstorm Cell Therapeutics, Inc. is a biotechnology company focused on developing adult stem cell therapies for neurodegenerative disorders like ALS, MS, and Parkinson's disease. It has a market cap of $9.48 million and reported a net profit loss of $3 million as of March 2025.
Overview:
Brainstorm Cell Therapeutics, Inc. is a biotechnology company engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Parkinson's disease (PD), among others, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.

Financial Snapshot:
Net Profit: -3 Million (Quarterly Results - Mar 2025)
Market Cap: USD 9.48 Million (Micro Cap)

Key Metrics:
P/E: NA (Loss Making)
Industry P/E: NA
Dividend Yield: 0.00%
Debt Equity: 0.00
Return on Equity: 155.00%
Price to Book: -1.27

Contact Details:
Address: 1325 Avenue of the Americas Fl 28, NEW YORK NY: 10019-6583
Tel: 1 201 4880460
Fax: 1 302 6555049
Website: http://www.brainstorm-cell.com/
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News